1. Home
  2. TRVG vs SABS Comparison

TRVG vs SABS Comparison

Compare TRVG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

N/A

Current Price

$4.26

Market Cap

422.6M

Sector

Technology

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$2.99

Market Cap

344.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRVG
SABS
Founded
2005
2014
Country
Germany
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.6M
344.8M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
TRVG
SABS
Price
$4.26
$2.99
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$5.95
★ $11.64
AVG Volume (30 Days)
187.2K
★ 637.7K
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 78.53
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.24
N/A
Revenue Next Year
$9.60
N/A
P/E Ratio
$16.98
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$2.10
52 Week High
$6.80
$5.15

Technical Indicators

Market Signals
Indicator
TRVG
SABS
Relative Strength Index (RSI) 31.35 34.77
Support Level $2.73 N/A
Resistance Level $5.77 $3.99
Average True Range (ATR) 0.39 0.20
MACD -0.17 -0.03
Stochastic Oscillator 0.43 28.12

Price Performance

Historical Comparison
TRVG
SABS

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: